Skip to main content
Jonathan Schwartz, MD, Oncology, New York, NY

JonathanDSchwartzMD

Oncology New York, NY

Gastrointestinal Cancer, Hematologic Oncology

Adjunct Associate Professor, Medicine - Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai

Dr. Schwartz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Schwartz's full profile

Already have an account?

  • Office

    1190 5th Ave
    # Mount
    New York, NY 10029
    Phone+1 212-241-6756
    Fax+1 212-423-0522

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1996 - 1999
  • Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital
    Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1992 - 1996
  • Washington University in St. Louis School of Medicine
    Washington University in St. Louis School of MedicineClass of 1992

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1993 - 2025

Publications & Presentations

PubMed

Abstracts/Posters

  • Changing the Natural History of Fanconi Anemia Complementation Group-A with Gene Therapy: Early Results of U.S. Phase I Study of Lentiviral-Mediated Ex-Vivo FANCA Gene...
    Jonathan D Schwartz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Hematopoietic Engraftment of Fanconi Anemia Patients through 3 Years after Gene Therapy
    Jonathan D Schwartz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • Rocket Pharmaceuticals Announces Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I
    Rocket Pharmaceuticals Announces Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-IDecember 9th, 2019